Global Crispr Genomic Cure Market Research Report 2023

Publication ID:

PB504242088

Publication Date:

May 17, 2023

Pages:

102

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Highlights
The global Crispr Genomic Cure market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Crispr Genomic Cure is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Crispr Genomic Cure is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Crispr Genomic Cure in Biomedical is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Crispr Genomic Cure include Abcam, Applied StemCel, Beam Therapeutics, CALYXT, Cellecta, Cellectis, CRISPR Therapeutics AG, Editas Medicine and ERS 鈥嬧€婫enomics, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Crispr Genomic Cure, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Crispr Genomic Cure.
The Crispr Genomic Cure market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Crispr Genomic Cure market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Crispr Genomic Cure companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Abcam
Applied StemCel
Beam Therapeutics
CALYXT
Cellecta
Cellectis
CRISPR Therapeutics AG
Editas Medicine
ERS 鈥嬧€婫enomics
Integrated DNA Technologies
Intellia Therapeutics
Merck KGaA
New England Biolabs
Precision BioSciences
Sangamo Therapeutics
Segment by Type
gRNA Design and Vector Construction
Cell Line and Engineering
Others
Segment by Application
Biomedical
Pharmaceutical
Agricultural
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Crispr Genomic Cure companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Crispr Genomic Cure Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 gRNA Design and Vector Construction
1.2.3 Cell Line and Engineering
1.2.4 Others
1.3 Market by Application
1.3.1 Global Crispr Genomic Cure Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Biomedical
1.3.3 Pharmaceutical
1.3.4 Agricultural
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Crispr Genomic Cure Market Perspective (2018-2029)
2.2 Crispr Genomic Cure Growth Trends by Region
2.2.1 Global Crispr Genomic Cure Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Crispr Genomic Cure Historic Market Size by Region (2018-2023)
2.2.3 Crispr Genomic Cure Forecasted Market Size by Region (2024-2029)
2.3 Crispr Genomic Cure Market Dynamics
2.3.1 Crispr Genomic Cure Industry Trends
2.3.2 Crispr Genomic Cure Market Drivers
2.3.3 Crispr Genomic Cure Market Challenges
2.3.4 Crispr Genomic Cure Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Crispr Genomic Cure Players by Revenue
3.1.1 Global Top Crispr Genomic Cure Players by Revenue (2018-2023)
3.1.2 Global Crispr Genomic Cure Revenue Market Share by Players (2018-2023)
3.2 Global Crispr Genomic Cure Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Crispr Genomic Cure Revenue
3.4 Global Crispr Genomic Cure Market Concentration Ratio
3.4.1 Global Crispr Genomic Cure Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Crispr Genomic Cure Revenue in 2022
3.5 Crispr Genomic Cure Key Players Head office and Area Served
3.6 Key Players Crispr Genomic Cure Product Solution and Service
3.7 Date of Enter into Crispr Genomic Cure Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Crispr Genomic Cure Breakdown Data by Type
4.1 Global Crispr Genomic Cure Historic Market Size by Type (2018-2023)
4.2 Global Crispr Genomic Cure Forecasted Market Size by Type (2024-2029)
5 Crispr Genomic Cure Breakdown Data by Application
5.1 Global Crispr Genomic Cure Historic Market Size by Application (2018-2023)
5.2 Global Crispr Genomic Cure Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Crispr Genomic Cure Market Size (2018-2029)
6.2 North America Crispr Genomic Cure Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Crispr Genomic Cure Market Size by Country (2018-2023)
6.4 North America Crispr Genomic Cure Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Crispr Genomic Cure Market Size (2018-2029)
7.2 Europe Crispr Genomic Cure Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Crispr Genomic Cure Market Size by Country (2018-2023)
7.4 Europe Crispr Genomic Cure Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Crispr Genomic Cure Market Size (2018-2029)
8.2 Asia-Pacific Crispr Genomic Cure Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Crispr Genomic Cure Market Size by Region (2018-2023)
8.4 Asia-Pacific Crispr Genomic Cure Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Crispr Genomic Cure Market Size (2018-2029)
9.2 Latin America Crispr Genomic Cure Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Crispr Genomic Cure Market Size by Country (2018-2023)
9.4 Latin America Crispr Genomic Cure Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Crispr Genomic Cure Market Size (2018-2029)
10.2 Middle East & Africa Crispr Genomic Cure Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Crispr Genomic Cure Market Size by Country (2018-2023)
10.4 Middle East & Africa Crispr Genomic Cure Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abcam
11.1.1 Abcam Company Detail
11.1.2 Abcam Business Overview
11.1.3 Abcam Crispr Genomic Cure Introduction
11.1.4 Abcam Revenue in Crispr Genomic Cure Business (2018-2023)
11.1.5 Abcam Recent Development
11.2 Applied StemCel
11.2.1 Applied StemCel Company Detail
11.2.2 Applied StemCel Business Overview
11.2.3 Applied StemCel Crispr Genomic Cure Introduction
11.2.4 Applied StemCel Revenue in Crispr Genomic Cure Business (2018-2023)
11.2.5 Applied StemCel Recent Development
11.3 Beam Therapeutics
11.3.1 Beam Therapeutics Company Detail
11.3.2 Beam Therapeutics Business Overview
11.3.3 Beam Therapeutics Crispr Genomic Cure Introduction
11.3.4 Beam Therapeutics Revenue in Crispr Genomic Cure Business (2018-2023)
11.3.5 Beam Therapeutics Recent Development
11.4 CALYXT
11.4.1 CALYXT Company Detail
11.4.2 CALYXT Business Overview
11.4.3 CALYXT Crispr Genomic Cure Introduction
11.4.4 CALYXT Revenue in Crispr Genomic Cure Business (2018-2023)
11.4.5 CALYXT Recent Development
11.5 Cellecta
11.5.1 Cellecta Company Detail
11.5.2 Cellecta Business Overview
11.5.3 Cellecta Crispr Genomic Cure Introduction
11.5.4 Cellecta Revenue in Crispr Genomic Cure Business (2018-2023)
11.5.5 Cellecta Recent Development
11.6 Cellectis
11.6.1 Cellectis Company Detail
11.6.2 Cellectis Business Overview
11.6.3 Cellectis Crispr Genomic Cure Introduction
11.6.4 Cellectis Revenue in Crispr Genomic Cure Business (2018-2023)
11.6.5 Cellectis Recent Development
11.7 CRISPR Therapeutics AG
11.7.1 CRISPR Therapeutics AG Company Detail
11.7.2 CRISPR Therapeutics AG Business Overview
11.7.3 CRISPR Therapeutics AG Crispr Genomic Cure Introduction
11.7.4 CRISPR Therapeutics AG Revenue in Crispr Genomic Cure Business (2018-2023)
11.7.5 CRISPR Therapeutics AG Recent Development
11.8 Editas Medicine
11.8.1 Editas Medicine Company Detail
11.8.2 Editas Medicine Business Overview
11.8.3 Editas Medicine Crispr Genomic Cure Introduction
11.8.4 Editas Medicine Revenue in Crispr Genomic Cure Business (2018-2023)
11.8.5 Editas Medicine Recent Development
11.9 ERS 鈥嬧€婫enomics
11.9.1 ERS 鈥嬧€婫enomics Company Detail
11.9.2 ERS 鈥嬧€婫enomics Business Overview
11.9.3 ERS 鈥嬧€婫enomics Crispr Genomic Cure Introduction
11.9.4 ERS 鈥嬧€婫enomics Revenue in Crispr Genomic Cure Business (2018-2023)
11.9.5 ERS 鈥嬧€婫enomics Recent Development
11.10 Integrated DNA Technologies
11.10.1 Integrated DNA Technologies Company Detail
11.10.2 Integrated DNA Technologies Business Overview
11.10.3 Integrated DNA Technologies Crispr Genomic Cure Introduction
11.10.4 Integrated DNA Technologies Revenue in Crispr Genomic Cure Business (2018-2023)
11.10.5 Integrated DNA Technologies Recent Development
11.11 Intellia Therapeutics
11.11.1 Intellia Therapeutics Company Detail
11.11.2 Intellia Therapeutics Business Overview
11.11.3 Intellia Therapeutics Crispr Genomic Cure Introduction
11.11.4 Intellia Therapeutics Revenue in Crispr Genomic Cure Business (2018-2023)
11.11.5 Intellia Therapeutics Recent Development
11.12 Merck KGaA
11.12.1 Merck KGaA Company Detail
11.12.2 Merck KGaA Business Overview
11.12.3 Merck KGaA Crispr Genomic Cure Introduction
11.12.4 Merck KGaA Revenue in Crispr Genomic Cure Business (2018-2023)
11.12.5 Merck KGaA Recent Development
11.13 New England Biolabs
11.13.1 New England Biolabs Company Detail
11.13.2 New England Biolabs Business Overview
11.13.3 New England Biolabs Crispr Genomic Cure Introduction
11.13.4 New England Biolabs Revenue in Crispr Genomic Cure Business (2018-2023)
11.13.5 New England Biolabs Recent Development
11.14 Precision BioSciences
11.14.1 Precision BioSciences Company Detail
11.14.2 Precision BioSciences Business Overview
11.14.3 Precision BioSciences Crispr Genomic Cure Introduction
11.14.4 Precision BioSciences Revenue in Crispr Genomic Cure Business (2018-2023)
11.14.5 Precision BioSciences Recent Development
11.15 Sangamo Therapeutics
11.15.1 Sangamo Therapeutics Company Detail
11.15.2 Sangamo Therapeutics Business Overview
11.15.3 Sangamo Therapeutics Crispr Genomic Cure Introduction
11.15.4 Sangamo Therapeutics Revenue in Crispr Genomic Cure Business (2018-2023)
11.15.5 Sangamo Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Abcam
Applied StemCel
Beam Therapeutics
CALYXT
Cellecta
Cellectis
CRISPR Therapeutics AG
Editas Medicine
ERS 鈥嬧€婫enomics
Integrated DNA Technologies
Intellia Therapeutics
Merck KGaA
New England Biolabs
Precision BioSciences
Sangamo Therapeutics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂